Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PCORI To Solicit More Head-To-Head Comparative Studies

Executive Summary

The Patient-Centered Outcomes Research Institute announces plans to encourage the submission of more proposals for head-to-head clinical comparative effectiveness studies. Among the research topics the institute will encourage are the Institute of Medicine’s top 100 priorities and recommendations from America’s Health Insurance Plans.

Advertisement

Related Content

Hepatitis C Drug Head-To-Head Comparative Studies Debated At PCORI Workshop
To Get The Most Out Of Health CER, Hire A Mathematician, Conferees Say
PCORI’s Selby Expects More Drug-Related Comparative Research In 2014
Drug-Related Topics Among PCORI Priorities For Large Pragmatic Clinical CER Trials
PCORI Funds Head-To-Head Drug Trial For Non-diabetic Neuropathy
PCORI Grant Process Begins, But Challenge Of Involving Nontraditional Researchers Remains
IOM Flags Top 100 Comparative Effectiveness Research Priorities; Drugs Mentioned Rarely

Topics

Advertisement
UsernamePublicRestriction

Register

PS055767

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel